Location History:
- Talant, FR (2019)
- Pouilley-les-Vignes, FR (2024)
Company Filing History:
Years Active: 2019-2024
Title: Sylvie Contal: Innovator in Cancer Treatment
Introduction
Sylvie Contal is a prominent inventor based in Talant, France. She has made significant contributions to the field of cancer treatment through her innovative research and development of new compounds. With a total of two patents to her name, her work focuses on the inhibition of specific interactions that play a crucial role in cancer progression.
Latest Patents
Sylvie Contal's latest patents include groundbreaking inventions aimed at treating cancer. The first patent involves inhibitors of the YAP/TAZ-TEAD interaction, which are essential in the development of cancer therapies. The invention relates to compounds of formula (I), wherein R, R, R, R, and R are defined in the description. The second patent also addresses the use of these compounds as inhibitors of the YAP/TAZ-TEAD interaction specifically for the treatment of malignant mesothelioma. This invention similarly involves compounds of formula (I), with R, R, R, R, and R defined in the description.
Career Highlights
Sylvie Contal is currently associated with Inventiva, a company dedicated to developing innovative therapies. Her work at Inventiva has positioned her as a key player in the research and development of cancer treatments. Her contributions have been instrumental in advancing the understanding of cancer biology and therapeutic strategies.
Collaborations
Throughout her career, Sylvie has collaborated with notable colleagues, including Martine Barth and Christian Montalbetti. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their shared field of research.
Conclusion
Sylvie Contal's work exemplifies the impact of innovative research in the fight against cancer. Her patents and collaborations highlight her commitment to developing effective treatments that can improve patient outcomes. Her contributions to the field are invaluable and continue to inspire future advancements in cancer therapy.